Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized intra-patient study of denovoSkin for deep partial and full-thickness burns
2023-507717-94-00Phase 3Authorised
- Sponsor
- CUTISS
- Start
- Jul 2024
- Modality
- Cell Therapies
- Countries
- 9
01
Overview
Phase 3, randomised trial in burn injury comparing denovoSkin (EHSG-KF) arm with Standard of care STSG arm (2 arms). Primary endpoint: Composite primary endpoint: wound closure and scar quality. Planned start Jul 2024; status: authorised.
02
Drugs
denovoSkin
03
Conditions
burn injury
Beyond the preview
Go deeper on 2023-507717-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507717-94-00.